BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27088318)

  • 1. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
    Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
    AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
    Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
    Auclair S; Liu F; Niu Q; Hou W; Churchyard G; Morgan C; Frahm N; Nitayaphan S; Pitisuthithum P; Rerks-Ngarm S; Kimata JT; Soong L; Franchini G; Robb M; Kim J; Michael N; Hu H
    PLoS Pathog; 2018 Feb; 14(2):e1006888. PubMed ID: 29474461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.
    Ahmed T; Borthwick NJ; Gilmour J; Hayes P; Dorrell L; Hanke T
    Vaccine; 2016 Feb; 34(9):1215-24. PubMed ID: 26784683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
    Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
    J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.
    Spentzou A; Bergin P; Gill D; Cheeseman H; Ashraf A; Kaltsidis H; Cashin-Cox M; Anjarwalla I; Steel A; Higgs C; Pozniak A; Piechocka-Trocha A; Wong J; Anzala O; Karita E; Dally L; Gotch F; Walker B; Gilmour J; Hayes P
    J Infect Dis; 2010 Mar; 201(5):720-9. PubMed ID: 20132004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
    Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
    Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.
    Boppana S; Fiore-Gartland A; Bansal A; Goepfert P
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31645444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
    McElrath MJ; De Rosa SC; Moodie Z; Dubey S; Kierstead L; Janes H; Defawe OD; Carter DK; Hural J; Akondy R; Buchbinder SP; Robertson MN; Mehrotra DV; Self SG; Corey L; Shiver JW; Casimiro DR;
    Lancet; 2008 Nov; 372(9653):1894-1905. PubMed ID: 19012957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
    Frahm N; DeCamp AC; Friedrich DP; Carter DK; Defawe OD; Kublin JG; Casimiro DR; Duerr A; Robertson MN; Buchbinder SP; Huang Y; Spies GA; De Rosa SC; McElrath MJ
    J Clin Invest; 2012 Jan; 122(1):359-67. PubMed ID: 22201684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses.
    Julg B; Williams KL; Reddy S; Bishop K; Qi Y; Carrington M; Goulder PJ; Ndung'u T; Walker BD
    J Virol; 2010 Jun; 84(11):5540-9. PubMed ID: 20335261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination.
    Rallón N; Mothe B; Lopez Bernaldo de Quiros JC; Plana M; Ligos JM; Montoya M; Muñoz-Fernández MA; Esteban M; Garcia F; Brander C; Benito JM;
    AIDS; 2016 Feb; 30(4):553-62. PubMed ID: 26558724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.